Skip to content
OpenCapital
Get started

NewAmsterdam Pharma Company NAMS EV / sales

EV / sales at other companies

Merck & Co. logo
Merck & Co.MRK
5.2×+1.2×
Amgen logo
AmgenAMGN
6.6×+0.1×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
5.5×+0.6×
Eli Lilly logo
Eli LillyLLY
11.9×-4.0×
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
2,591.9×+2,580×

Other financials

Income statement

See full
Revenue$3.0M+2.1%
Operating income-$58.4M+15.2%
Net income-$48.4M-22.6%
EPS (diluted)-$0.40-17.6%

Balance sheet

See full
Cash & equivalents$457.6M-38.9%
Total debt$23.0K-94.1%
Total equity$665.2M-14.4%
Total assets$732.6M-10.5%

Cash flow

See full
Operating cash flow-$30.6M+16.1%
CapEx$38.0K+138%
Free cash flow-$30.6M+16.0%

Valuation

See full
Market cap$3.67B+63.7%

Profitability

See full
Operating margin-953.6%-3,536pp
Net margin-942.8%-3,477pp
FCF margin-630.1%-6,324pp

Returns & leverage

See full
Return on equity-29.5%-1.8pp
Current ratio9.8×-10.2×

Where this comes from

Calculated from NewAmsterdam Pharma Company’s reported figures.

enterprise value/total revenue=142.8×

Based on the most recent quarter.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NewAmsterdam Pharma Company's EV / sales?
NewAmsterdam Pharma Company (NAMS) reported EV / sales of 142.8× in Q1 2026.
How has NewAmsterdam Pharma Company's EV / sales changed year-over-year?
NewAmsterdam Pharma Company's EV / sales increased by 348.9% year-over-year, from 31.8× to 142.8×.
What is the long-term trend for NewAmsterdam Pharma Company's EV / sales?
Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's EV / sales has grown at a 214.2% compound annual growth rate (CAGR), from 5× to 155×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.